BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28625657)

  • 1. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
    Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
    Chen J; Cui JD; Guo XT; Cao X; Li Q
    Cancer Med; 2018 Apr; 7(4):1394-1403. PubMed ID: 29493886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
    Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
    Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
    Kim N; Cho A; Watanabe H; Choi YL; Aziz M; Kassner M; Joung JG; Park AK; Francis JM; Bae JS; Ahn SM; Kim KM; Park JO; Park WY; Ahn MJ; Park K; Koo J; Yin HH; Cho J
    Oncotarget; 2016 Mar; 7(12):13797-809. PubMed ID: 26883194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-depth analysis shows synergy between erlotinib and miR-34a.
    Zhao J; Kelnar K; Bader AG
    PLoS One; 2014; 9(2):e89105. PubMed ID: 24551227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
    Russo A; Franchina T; Ricciardi GRR; Smiroldo V; Picciotto M; Zanghì M; Rolfo C; Adamo V
    Crit Rev Oncol Hematol; 2017 Sep; 117():38-47. PubMed ID: 28807234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
    Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
    Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
    Asami K
    Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.
    Singh M; Jadhav HR
    Drug Discov Today; 2018 Mar; 23(3):745-753. PubMed ID: 29031620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
    Noda S; Kanda S
    Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
    Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
    Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.